Insulet Corporation (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Insulet Corporation (NASDAQ:PODD) have earned an average recommendation of “Moderate Buy” from the twenty-two ratings firms that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $352.1053.

Several research analysts have weighed in on the company. Leerink Partners boosted their price target on Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a report on Tuesday, October 14th. JPMorgan Chase & Co. boosted their price target on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Rothschild & Co Redburn boosted their price target on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Insulet in a report on Thursday, August 7th.

Insulet Trading Up 0.6%

Shares of Insulet stock opened at $328.97 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet has a 1 year low of $226.50 and a 1 year high of $353.50. The company has a market capitalization of $23.16 billion, a P/E ratio of 99.99, a P/E/G ratio of 2.73 and a beta of 1.40. The business has a 50 day moving average price of $327.04 and a 200 day moving average price of $303.28.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same period in the previous year, the firm posted $0.55 EPS. The company’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that Insulet will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

A number of institutional investors and hedge funds have recently made changes to their positions in PODD. Larson Financial Group LLC increased its holdings in shares of Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 81 shares during the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of Insulet during the 1st quarter worth $26,000. SouthState Corp increased its holdings in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the last quarter. True Wealth Design LLC increased its holdings in shares of Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the last quarter. Finally, Kozak & Associates Inc. acquired a new stake in shares of Insulet during the 2nd quarter worth $32,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.